1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Real-time Estimate Cboe Europe  -  08:58 2022-08-12 am EDT
314.98 CHF   +1.56%
04:47aEuropean shares rise as healthcare rebounds, travel stocks gain
RE
01:00aRoche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
AQ
01:00aRoche Announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche Wins US FDA Nod For Use Of Spinal Muscular Atrophy Drug In Babies

05/31/2022 | 01:22am EDT


© MT Newswires 2022
All news about ROCHE HOLDING AG
04:47aEuropean shares rise as healthcare rebounds, travel stocks gain
RE
01:00aRoche announces U.S. FDA approval of Xofluza to treat influenza in children aged five y..
AQ
01:00aRoche Announces U.S. FDA approval of Xofluza to treat influenza in children aged five y..
CI
08/11Roche's Genentech Gets US FDA Nod For Influenza Drug In Children Aged Five To 12
MT
08/11Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five an..
BU
08/11GENENTECH : FDA Approves Xofluza to Treat Influenza in Children Aged 5 and Older
DJ
08/11GLOBAL MARKETS LIVE : Walt Disney, Bank of America, Sonos, ABB, Roche...
MS
08/11Chugai Pharmaceutical Co., Ltd. - Anti-C5 Recycling Antibody Crovalimab Obtains Priorit..
AQ
08/11ROCHE HOLDINGS AG : Deutsche Bank reiterates its Neutral rating
MD
08/11Roche Obtains US FDA Approval For Expansion Of Ventana Diagnostic Test
MT
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 64 190 M 68 260 M 68 260 M
Net income 2022 14 826 M 15 766 M 15 766 M
Net Debt 2022 10 272 M 10 923 M 10 923 M
P/E ratio 2022 16,7x
Yield 2022 3,11%
Capitalization 256 B 273 B 273 B
EV / Sales 2022 4,16x
EV / Sales 2023 4,03x
Nbr of Employees 100 920
Free-Float 82,4%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 310,15 CHF
Average target price 374,13 CHF
Spread / Average Target 20,6%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-18.19%272 759
JOHNSON & JOHNSON-2.30%439 441
ELI LILLY AND COMPANY9.03%286 164
PFIZER, INC.-18.22%271 020
ABBVIE INC.4.93%251 211
NOVO NORDISK A/S6.37%248 905